Supriya Lifescience has received Good Manufacturing Practice (GMP) certification from Brazil’s Regulatory Authority, ANVISA, for its manufacturing facility located in Lote Parshuram, Ratnagiri District, Maharashtra, India.
The recent clearance is expected to expedite and streamline the registration process for the company’s remaining APIs, facilitating a smoother pathway for their introduction into the Brazilian market.
Supriya Lifescience’s Lote Factory underwent a rigorous inspection by ANVISA, and received “Zero” observations in compliance. highest quality standards and employing advanced production and manufacturing techniques.
Dr Satish Wagh, Chairman and Managing Director, Supriya Lifescience stated, “It is a privilege for us to have obtained the GMP accreditation from ANVISA, which clearly demonstrates our strength of manufacturing capabilities from the state-of-the-art world class facility at Lote Parshuram, Ratnagiri District, in Maharashtra. This certification not only enhances our presence in the Brazilian market but also strengthens our reputation as a trustworthy and quality-oriented pharmaceutical company and will increase our presence in the South American market.”